MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
miRagen Therapeutics Secures $41 million Series C Financing to Advance Two MicroRNA Programs into Clinical Trials.
Guest UserNovember 10, 2015
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology.

Guest UserJanuary 11, 2016
Next

Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Studay for Acute Kidney Injury.

Guest UserJuly 7, 2015

© 2010-2025 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact